Bicyclic Pyridine TAAR1 Agonists for Selective Neuropsychiatric Therapy

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatments for neuropsychiatric disorders, such as schizophrenia and depression, lack effective compounds that target the trace amine-associated receptor TAAR1, which is implicated in regulating monoamine functions and neurotransmission.

Innovation Solution

Development of novel bicyclic pyridine derivatives with agonist activity on the TAAR1 receptor, offering potential therapeutic agents for neuropsychiatric disorders.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If existing treatments for neuropsychiatric disorders are used, then current therapeutic effects are achieved, but effective compounds targeting TAAR1 receptor are lacking

Engineering Contradiction:

Improvetherapeutic effectivenessVSAvoidreceptor targeting capability

Core Design Contradiction:

ReliabilityVSAdaptability or versatility

Solution Approach 1:

The patent modifies molecular parameters of pyridine derivatives by introducing specific substituents at defined positions (R1-R6 groups) to optimize TAAR1 receptor binding affinity and agonist activity, thereby achieving effective therapeutic targeting

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The invention creates composite molecular structures combining pyridine core with various substituent groups (aromatic rings, heterocyclic rings, alkyl chains) to achieve both high TAAR1 selectivity and potent agonist activity

Inventive Principle:

Principle #40Composite materials

2Reliability

If compounds with TAAR1 agonist activity are developed, then antipsychotic and antidepressant effects are achieved, but selectivity against other GPCRs and hERG channels must be ensured

Engineering Contradiction:

Improvetherapeutic efficacyVSAvoidoff-target effects on other GPCRs and hERG channels

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent introduces specific substituent patterns at particular positions of the pyridine ring system to create local chemical features that enhance TAAR1 binding while avoiding interaction motifs that would activate other GPCRs or hERG channels

Inventive Principle:

Principle #3Local quality

Solution Approach 2:

The invention carefully designs molecular structures that exploit the selectivity of TAAR1 receptor to achieve therapeutic effects while inherently avoiding the harmful off-target effects on other receptor systems through structural exclusion criteria

Inventive Principle:

Principle #22Blessing in disguise (Convert harm into benefit)

Data Source

PatentUS20260035379A1Bicyclic pyridine derivative

Publication Date: 2026.02.05 SUMITOMO PHARMA CO LTD

AI summary

The present disclosure provides bicyclic pyridine derivatives.A compound represented by formula I:or a pharmaceutically acceptable salt thereof,whereinX is a oxygen atom, sulfur atom, NR, or CR′R″, n is 0 or 1, R1, R2a, R2b, R2c, R2d, R, R′ and R″ are each independently a hydrogen atom, a halogen atom, optionally substituted C1-6 alkyl, or an optionally substituted C6-10 aryl, or two of R2a, R2b, R2c, R2d, R, R′, and R″, together with a carbon atom or a nitrogen atom to which they are attached, form a 3- to 6-membered saturated carbocyclic ring or saturated heterocyclic ring, and R3a, R3b, R3c and R5a and R5b, are as defined in the description.